Biden Pushes for Medicare, Medicaid Coverage of Weight-Loss Drugs

The Biden administration has proposed a new rule requiring Medicare and Medicaid to cover anti-obesity drugs, such as Novo Nordisk's Ozempic and Wegovy, which could expand access to these medications for millions of Americans. This move reinterprets existing laws that currently bar Medicare from covering weight-loss drugs, potentially costing taxpayers $40 billion over the next decade. The proposal aims to address obesity as a chronic disease, but may face opposition from lawmakers and pharmaceutical critics.